Global Recombinant DNA Vaccine Market Size, Share and Trends Analysis Report, By Type (Subunit and Live Attenuated), By Application (Human Papillomavirus, Hepatitis B, Rotavirus, Herpes Zoster, Meningococcal B, and Others), Forecast (2022-2028)

The global recombinant DNA vaccine market is anticipated to grow at a significant CAGR of 11.7% during the forecast period (2022-2028). Recombinant DNA vaccine is used to develop antigens for many different pathogens, such as influenza, HIV, malaria, TB, and leishmaniasis, leading to the induction of immune responses against these etiologic agents in several animal models. The global recombinant DNA vaccine market is growing due to the rising prevalence of viral diseases globally as the DNA vaccines provide effectiveness and safety to the patients getting immunized. These recombinant DNA vaccines can be produced in very large quantities which makes them easily available in the market in a shorter period of time. Additionally, the increasing technological advancement in recombinant DNA and genetics is boosting the research and development activities of the vaccine.

 

The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new vaccine launches, to stay competitive in the market. For instance-

 

• In February 2022, Sanofi announced their recombinant protein COVID-19 vaccine which is under Phase-III trial. This drug is developed by Sanofi in the collaboration with GlaxoSmithKline plc and the US Biomedical Advanced Research and Development Authority.
• In August 2021, Zydus Group announced that India’s drug regulator has approved a three-dose ZyCoV-D vaccine which is the world’s first DNA vaccine to prevent COVID-19 infection.
• In April 2020, AstraZeneca announced their manufacturing and distribution collaboration with the University of Oxford for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2.
• In December 2019, USFDA approved the Ervebo recombinant viral vaccine, the first vaccine for the prevention of EVD, caused by Zaire ebolavirus for individuals of age 18 years and above.

 

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Sanofi S.A., Pfizer Inc., Merck & Co., Inc., Novartis AG, and GlaxoSmithKline plc, among others.

 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Global Recombinant DNA Vaccine Market Report by Segment

By Type

• Subunit
• Live Attenuated

By Application

• Human Papillomavirus
• Hepatitis B
• Rotavirus
• Herpes Zoster
• Meningococcal B
• Others

Global Recombinant DNA Vaccine Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa